Media.Player

Platelet Lysate Gel for Wound Healing and Revascularization Therapy

標題

Platelet Lysate Hydrogel for Endothelial Cell and Mesenchymal Stem Cell-Directed Neovascularization

詳細技術說明

ApplicationPlatelet lysate (PL) gel for localized growth factor delivery, wound healing and as a delivery vehicle for cellular therapies.Key BenefitsIncreases human mesenchymal stem cell (MSC) expansion capacity compared to fetal bovine serum.Derived from human blood products, reducing risk of contamination from foreign organism.Enables use of lower initial cell dose due to increased cell expansion of MSCs.PL degrades slower than fibrin, leading to longer sustained nutrient release.Market SummaryPeripheral arterial disease (PAD) is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs. As many as 20% of the U.S. population will have PAD by the age of 65. PAD can increase the risk of heart attack or stroke by 4-5 times and, in advanced stages, may lead to critical limb ischemia (CLI). CLI occurs when injuries or infections progress and lead to tissue death (gangrene), sometimes requiring amputation of the affected limb. Despite optimistic results of cellular and regenerative therapy trials in PAD, the effectiveness of cellular therapies in preventing amputations has yet to be proven, due in part to limited retention of cells after delivery.Technical SummaryMesenchymal stem cells (MSCs) are an ideal cell type for vascular regeneration via angiogenesis and arteriogenesis. Researchers have developed a platelet lysate (PL) hydrogel for improving MSC retention, survival, and engraftment into the desired tissue beds. The researchers have shown that PL increases human MSC expansion capacity compared to fetal bovine serum and can re-stimulate senescing MSCs. PL is also rich in a variety of endogenous growth factors, including platelet derived growth factor-BB, which has been shown to improve MSC engraftment into tissues. Because PL is derived entirely from human blood products, it does not pose a risk of contamination from a foreign organism. The potential increase in cell expansion of MSCs may enable the use of a lower initial cell dose to achieve therapeutic benefit.Developmental StageIn vitro and in vivo data available.Publications: Publications: Robinson, S. T. et al. (2016). Acta Biomaterialia, 36, 86-98.

*Abstract

None

*Principal Investigation

Name: Luke Brewster, Assistant Professor

Department: SOM: Surgery: Vascular

Name: Scott Robinson, Vascular Surgery Fellow

Department:

Name: Ian Copland, Assistant Professor

Department: SOM: HMO: BMT

申請日期

Mar 3, 2017

國家/地區

美國